Menu

Latest news & events

Studentbeurzen Nederlandse Hartstichting 2022 Call for Proposals - Deadline 1 september 2023

Studentbeurzen Nederlandse Hartstichting 2022 Call for Proposals - Deadline 1 september 2023

11 May 2023

Binnen het dr. E. Dekker-programma voor persoonsgebonden beurzen stelt de Nederlandse Hartstichting per universiteit twee studentbeurzen beschikbaar. De beurs bedraagt maximaal € 3.000.

Read more
Harry Crijns Research Grant - Deadline 17 september 2023

Harry Crijns Research Grant - Deadline 17 september 2023

25 April 2023

De Harry Crijns Research Grant, in het leven geroepen door het Hart en vaat onderzoekfonds Limburg, in te stelle wordt periodiek toegekend aan jonge wetenschappers die zich bezighouden met klinisch cardiovasculair onderzoek en daarmee bijdragen aan de realisering van de doelstellingen van de foundation.

Read more
More newsMore events
Carim Maastricht
Carim Maastricht

Harry Crijns

Professor

Harry Crijns is professor and chair of Cardiology and board member of the Cardiovascular Research Institute Maastricht (CARIM) at Maastricht UMC+. He studied medicine at the University of Amsterdam and was trained in cardiology and electrophysiology in Groningen and Maastricht. He is a Fellow of the ESC and a past board member of the EHRA. He is also past Chair of the Netherlands Society of Cardiology. He served on several guidelines committees for the management of AF. Currently he is the chairman of the scientific advisory board of the Dutch Heart Foundation.

His primary research focus continues to be atrial fibrillation (AF). He founded the RACE trials in the Netherlands and led the Euro Heart Survey on AF (ESC). He has established his reputation by introducing innovative concepts for diagnosis and treatment of AF by showing that - quite contrary to longstanding beliefs - electrical management does not change prognosis. This revolutionised management of the arrhythmia worldwide with the effect that major interventions like electrical cardioversion, catheter ablation and antiarrhythmic drug therapy are applied in a much more personalized fashion.

Subsequently his group showed that rate control in AF can be individualized thereby removing the previously used strict heart rate targets from the international guidelines. He also performed the Euro Heart Survey on AF and made many contributions to the field of stroke management in AF, such as the construction of well-recognised AF specific risk stratification scores for AF progression (HATCH), ischemic stroke (CHA2DS2-VASc) and major bleeding (HAS-BLED). These scores have practically conquered the medical AF community and improved patient care whilst boosting new clinical research throughout the world.

His research group now focusses on recent-onset AF, hybrid AF ablation, upstream therapy and vascular mechanisms for AF progression and stroke in idiopathic atrial fibrillation. He is (co-)author on over 650 scientific articles, with 56,677 citations and Hirsch-index of 100.

Harry-crijns

Department of Cardiology
P. Debyelaan 25, 6229 HX Maastricht 
PO Box 5800, 6202 AZ Maastricht


  • 2023
    • Altintas, S., van Workum, S., Kok, M., Joosen, I. A. P. G., Versteylen, M. O., Nelemans, P. J., Wildberger, J. E., Crijns, H. J. G. M., Das, M., & Kietselaer, B. L. J. H. (2023). BMI is not independently associated with coronary artery calcification in a large single-center CT cohort. Obesity science & practice, 9(2), 172-178. https://doi.org/10.1002/osp4.636
    • Lambiase, P. D., Sanders, P., & Crijns, H. J. G. M. (2023). The year in cardiovascular medicine 2022: the top 10 papers in arrhythmias. European Heart Journal, 44(5), 345–347. https://doi.org/10.1093/eurheartj/ehac753
    • Nguyen, B. O., Weberndorfer, V., Crijns, H. J. G. M., Geelhoed, B., Ten Cate, H., Spronk, H., Kroon, A., De With, R., Al-Jazairi, M., Maass, A. H., Blaauw, Y., Tieleman, R. G., Hemels, M. E. W., Luermans, J., de Groot, J., Allaart, C. P., Elvan, A., De Melis, M., Scheerder, C., ... Rienstra, M. (2023). Prevalence and determinants of atrial fibrillation progression in paroxysmal atrial fibrillation. Heart, 109(3), 186-194. https://doi.org/10.1136/heartjnl-2022-321027
    • van der Velden, R. M. J., Pluymaekers, N. A. H. A., Dudink, E. A. M. P., Luermans, J. G. L. M., Meeder, J. G., Heesen, W. F., Lenderink, T., Widdershoven, J. W. M. G., Bucx, J. J. J., Rienstra, M., Kamp, O., van Opstal, J. M., Kirchhof, C. J. H. J., van Dijk, V. F., Swart, H. P., Alings, M., Van Gelder, I. C., Crijns, H. J. G. M., & Linz, D. (2023). Mobile health adherence for the detection of recurrent recent-onset atrial fibrillation. Heart, 109(1), 26-33. https://doi.org/10.1136/heartjnl-2022-321346
  • 2022
    • Martinek, M., Crijns, H. J. G. M., Essers, B. A. B., Wiesinger, R., & Pruckner, G. (2022). Healthcare Utilization and Outcomes in Atrial Fibrillation Patients Treated by Drug Therapy versus a Catheter Ablation Strategy-A Middle European Propensity Score Matched Cohort Study. Journal of Cardiovascular Development and Disease, 9(12). https://doi.org/10.3390/jcdd9120451
    • Zeemering, S., Isaacs, A., Winters, J., Maesen, B., Bidar, E., Dimopoulou, C., Guasch, E., Batlle, M., Haase, D., Hatem, S. N., Kara, M., Kääb, S., Mont, L., Sinner, M. F., Wakili, R., Maessen, J., Crijns, H. J. G. M., Fabritz, L., Kirchhof, P., ... Schotten, U. (2022). Atrial fibrillation in the presence and absence of heart failure enhances expression of genes involved in cardiomyocyte structure, conduction properties, fibrosis, inflammation, and endothelial dysfunction. Heart Rhythm, 19(12), 2115-2124. https://doi.org/10.1016/j.hrthm.2022.08.019
    • Vitolo, M., Proietti, M., Malavasi, V. L., Bonini, N., Romiti, G. F., Imberti, J. F., Fauchier, L., Marin, F., Nabauer, M., Potpara, T. S., Dan, G-A., Kalarus, Z., Maggioni, A. P., Lane, D. A., Lip, G. Y. H., Boriani, G., ESC-EHRA EORP-AF Long-Term General Registry Investigators, Erküner, Ö., & Crijns, H. (2022). Adherence to the "Atrial fibrillation Better Care" (ABC) pathway in patients with atrial fibrillation and cancer: A report from the ESC-EHRA EURObservational Research Programme in atrial fibrillation (EORP-AF) General Long-Term Registry. European journal of internal medicine, 105, 54-62. https://doi.org/10.1016/j.ejim.2022.08.004
    • Eckardt, L., Sehner, S., Suling, A., Borof, K., Breithardt, G., Crijns, H. J. G. M., Goette, A., Wegscheider, K., Zapf, A., Camm, A. J., Metzner, A., & Kirchhof, P. (2022). Attaining sinus rhythm mediates improved outcome with early rhythm control therapy of atrial fibrillation: the EAST - AFNET 4 trial. European Heart Journal, 43(40), 4127-4144. https://doi.org/10.1093/eurheartj/ehac471
    • van der Velden, R. M. J., Hermans, A. N. L., Pluymaekers, N. A. H. A., Gawalko, M., Elliott, A., Hendriks, J. M., Franssen, F. M. E., Slats, A. M., van Empel, V. P. M., Van Gelder, I. C., Thijssen, D. H. J., Eijsvogels, T. M. H., Leue, C., Crijns, H. J. G. M., Linz, D., & Simons, S. O. (2022). Dyspnea in patients with atrial fibrillation: Mechanisms, assessment and an interdisciplinary and integrated care approach. IJC Heart and Vasculature, 42, [101086]. https://doi.org/10.1016/j.ijcha.2022.101086
    • Garcia, R., Clouard, M., Plank, F., Degand, B., Philibert, S., Laurent, G., Poupin, P., Sakhy, S., Gras, M., Stühlinger, M., Szegedi, N., Herczeg, S., Simon, J., Crijns, H. J. G. M., Marijon, E., Christiaens, L., & Guenancia, C. (2022). Asymptomatic left circumflex artery stenosis is associated with higher arrhythmia recurrence after persistent atrial fibrillation ablation. Frontiers in cardiovascular medicine, 9, [873135]. https://doi.org/10.3389/fcvm.2022.873135
Overview